Moreover, in reducing hepcidin levels, HIF-PH inhibition has the potential to increase access to existing iron stores and avoid the need to administer iron; potentially reducing risk of iron overload and bypassing the principal cause of ESA resistance and resistant anemia of CKD. The gene discussed is HAMP; the disease is chronic kidney disease.